艾塞那肽在肥胖治疗中的潜在应用。
Potential use of exenatide for the treatment of obesity.
机构信息
University of Texas Health Science Center at San Antonio, Division of Diabetes, Department of Medicine, Texas, USA.
出版信息
Expert Opin Investig Drugs. 2011 Dec;20(12):1717-22. doi: 10.1517/13543784.2011.630660. Epub 2011 Oct 24.
Abstract
INTRODUCTION
Obesity is a major health threat in the Western world because of its high incidence and prevalence, and its association with metabolic and cardiovascular disease as well as cancer. The reduction of food intake in obese patients can be achieved only transiently (generally for no longer than 6 months), in the absence of concomitant pharmacological therapy. Only bariatric surgery provides a means to increase satiety and/or decrease nutrient absorption in obese patients, in the long term.
AREAS COVERED
This article reviews the available pharmacological treatments for obesity as well as the pharmacology and mechanism of action of exenatide in obese type 2 diabetic patients.
EXPERT OPINION
Exenatide is a potential new candidate treatment for obesity, possibly in combination with other hormones that increase satiety (leptin) and slow gastric emptying (amylin).
摘要
简介
肥胖是西方世界的一个主要健康威胁，因为它的发病率和患病率都很高，而且它与代谢和心血管疾病以及癌症有关。在没有伴随药物治疗的情况下，肥胖患者的食物摄入量只能暂时减少（通常不超过 6 个月）。只有减肥手术才能为肥胖患者提供一种长期增加饱腹感和/或减少营养吸收的方法。
涵盖领域
本文综述了目前用于肥胖症的药物治疗方法，以及 exenatide 在肥胖 2 型糖尿病患者中的药理学和作用机制。
专家意见
Exenatide 可能是肥胖症的一种新的潜在候选治疗方法，可能与其他增加饱腹感（瘦素）和减缓胃排空（胰淀素）的激素联合使用。
相似文献
1
Potential use of exenatide for the treatment of obesity.艾塞那肽在肥胖治疗中的潜在应用。
Expert Opin Investig Drugs. 2011 Dec;20(12):1717-22. doi: 10.1517/13543784.2011.630660. Epub 2011 Oct 24.
2
[Metabolic control and weight loss in patients with obesity and type 2 diabetes mellitus, treated with exenatide].[艾塞那肽治疗肥胖和2型糖尿病患者的代谢控制与体重减轻]
Med Clin (Barc). 2012 Dec 1;139(13):572-8. doi: 10.1016/j.medcli.2011.10.025. Epub 2011 Dec 28.
3
Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes.肠促胰岛素类似物艾塞那肽治疗2型糖尿病的代谢效应
Vasc Health Risk Manag. 2006;2(1):69-77. doi: 10.2147/vhrm.2006.2.1.69.
4
Exenatide: a novel approach for treatment of type 2 diabetes.艾塞那肽：一种治疗2型糖尿病的新方法。
South Med J. 2006 Nov;99(11):1271-9. doi: 10.1097/01.smj.0000240730.86237.b6.
5
How to fight obesity with antidiabetic drugs: targeting gut or kidney?如何使用抗糖尿病药物对抗肥胖：针对肠道还是肾脏？
Minerva Endocrinol. 2015 Mar;40(1):71-83. Epub 2014 Nov 4.
6
Exenatide: from the Gila monster to the pharmacy.艾塞那肽：从吉拉毒蜥到药房。
J Am Pharm Assoc (2003). 2006 Jan-Feb;46(1):44-52; quiz 53-5. doi: 10.1331/154434506775268698.
7
Managed care perspective on three new agents for type 2 diabetes.管理式医疗对2型糖尿病三种新型药物的看法。
J Manag Care Pharm. 2008 May;14(4):363-80. doi: 10.18553/jmcp.2008.14.4.363.
8
Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes.艾塞那肽对2型糖尿病患者肥胖及伴有肝酶升高的非酒精性脂肪性肝病的益处。
Diabetes Metab Res Rev. 2014 Sep;30(6):521-9. doi: 10.1002/dmrr.2561.
9
10
Effects of exenatide on metabolic parameters/control in obese Japanese patients with type 2 diabetes.艾塞那肽对日本肥胖2型糖尿病患者代谢参数/控制情况的影响。
Endocr J. 2014;61(4):365-72. doi: 10.1507/endocrj.ej14-0009. Epub 2014 Jan 22.
引用本文的文献
1
Glucagon-like peptide-1 receptor agonists: Evolution, gastrointestinal adverse effects, and future directions.胰高血糖素样肽-1受体激动剂：演变、胃肠道不良反应及未来方向。
World J Gastrointest Pharmacol Ther. 2025 Sep 5;16(3):107148. doi: 10.4292/wjgpt.v16.i3.107148.
2
The Effect of Exenatide on Platelets Ratio Index and Fibrosis-4 Index in Obese Patients With Diabetes Mellitus.艾塞那肽对肥胖糖尿病患者血小板比率指数和纤维化-4指数的影响
Int J Endocrinol. 2025 Apr 28;2025:6332117. doi: 10.1155/ije/6332117. eCollection 2025.
3
Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data.用于治疗2型糖尿病和肥胖症的双靶点和三靶点肠道肽激动剂即将问世。临床前和临床数据概述
Curr Obes Rep. 2025 Apr 11;14(1):34. doi: 10.1007/s13679-025-00623-1.
4
Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential.揭示胰高血糖素样肽-1的多方面作用：生理功能与治疗潜力
Toxicol Rep. 2025 Jan 16;14:101895. doi: 10.1016/j.toxrep.2025.101895. eCollection 2025 Jun.
5
A Comprehensive Review on Weight Gain following Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists for Obesity.肥胖患者停用胰高血糖素样肽-1 受体激动剂后体重增加的全面综述。
J Obes. 2024 May 10;2024:8056440. doi: 10.1155/2024/8056440. eCollection 2024.
6
Alternate-day fat diet and exenatide modulate the brain leptin JAK2/STAT3/SOCS3 pathway in a fat diet-induced obesity and insulin resistance mouse model.隔日高脂饮食和艾塞那肽在高脂饮食诱导的肥胖和胰岛素抵抗小鼠模型中调节大脑瘦素JAK2/STAT3/SOCS3信号通路。
Arch Med Sci. 2023 Feb 1;19(5):1508-1519. doi: 10.5114/aoms/158534. eCollection 2023.
7
Mechanisms of action of incretin receptor based dual- and tri-agonists in pancreatic islets.基于肠促胰岛素受体的双重和三重激动剂在胰岛中的作用机制。
Am J Physiol Endocrinol Metab. 2023 Nov 1;325(5):E595-E609. doi: 10.1152/ajpendo.00236.2023. Epub 2023 Sep 20.
8
GLP-1 receptor agonists for the treatment of obesity: Role as a promising approach.GLP-1 受体激动剂治疗肥胖症：一种有前途的方法。
Front Endocrinol (Lausanne). 2023 Feb 1;14:1085799. doi: 10.3389/fendo.2023.1085799. eCollection 2023.
9
Behavioural and neurochemical mechanisms underpinning the feeding-suppressive effect of GLP-1/CCK combinatorial therapy.GLP-1/CCK 联合治疗抑制摄食作用的行为和神经化学机制。
Mol Metab. 2021 Jan;43:101118. doi: 10.1016/j.molmet.2020.101118. Epub 2020 Nov 19.
10
An overview of glucagon-like peptide-1 receptor agonists for the treatment of metabolic syndrome: A drug repositioning.用于治疗代谢综合征的胰高血糖素样肽-1受体激动剂概述：药物重新定位
Iran J Basic Med Sci. 2020 May;23(5):556-568. doi: 10.22038/ijbms.2020.41638.9832.
本文引用的文献
1
Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes.在二甲双胍治疗的 2 型糖尿病患者中，经过 3 年的治疗，艾塞那肽对β细胞功能测量指标的影响。
Diabetes Care. 2011 Sep;34(9):2041-7. doi: 10.2337/dc11-0291.
2
The safety of incretin-based therapies--review of the scientific evidence.基于肠促胰岛素的治疗安全性——科学证据综述。
J Clin Endocrinol Metab. 2011 Jul;96(7):2027-31. doi: 10.1210/jc.2011-0599.
3
New drug targets for the treatment of obesity.治疗肥胖的新药物靶点。
Clin Pharmacol Ther. 2011 Jul;90(1):40-51. doi: 10.1038/clpt.2011.82. Epub 2011 Jun 8.
4
Exenatide once weekly in type 2 diabetes mellitus.艾塞那肽每周一次用于2型糖尿病
Expert Opin Pharmacother. 2011 Jun;12(8):1297-1303. doi: 10.1517/14656566.2011.573145.
5
Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years.艾塞那肽每周一次治疗可在 2 年内维持血糖控制和体重减轻的改善。
BMC Endocr Disord. 2011 Apr 29;11:9. doi: 10.1186/1472-6823-11-9.
6
A cohort study of acute pancreatitis in relation to exenatide use.一项关于急性胰腺炎与 exenatide 使用相关的队列研究。
Diabetes Obes Metab. 2011 Jun;13(6):559-66. doi: 10.1111/j.1463-1326.2011.01376.x.
7
The pharmacological treatment and management of obesity.肥胖的药理学治疗与管理。
Postgrad Med. 2011 Jan;123(1):34-44. doi: 10.3810/pgm.2011.01.2243.
8
Obesity in 2010: the future of obesity medicine: where do we go from here?2010年的肥胖问题：肥胖医学的未来：我们从这里走向何方？
Nat Rev Endocrinol. 2011 Feb;7(2):69-70. doi: 10.1038/nrendo.2010.231.
9
An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.每周一次胰高血糖素样肽-1 受体激动剂概述——现有疗效和安全性数据及未来展望。
Diabetes Obes Metab. 2011 May;13(5):394-407. doi: 10.1111/j.1463-1326.2011.01357.x. Epub 2011 Jan 5.
10
Effect of exenatide on fat deposition and a metabolic profile in patients with metabolic syndrome.艾塞那肽对代谢综合征患者脂肪沉积和代谢特征的影响。
Metab Syndr Relat Disord. 2011 Feb;9(1):31-4. doi: 10.1089/met.2010.0025. Epub 2010 Sep 28.
Zotero 插件